In Q1 FY2026, Indivior reported revenue of $317 million, up 19.2% year-over-year. Net income was $89 million, a 89.4% increase, and operating income rose 107.6% to $137 million. Diluted EPS was $0.69, up 81.6%. The company had $175 million in cash, $486 million in long-term debt, and negative equity of $144 million.
•Revenue grew 19.2% YoY to $317 million.
•Net income surged 89.4% to $89 million.
•Operating income more than doubled to $137 million.
•Diluted EPS increased 81.6% to $0.69.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Indivior Pharmaceuticals provides the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders globally. It develops medicines to treat substance use disorders.
The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD).
Additionally, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. The company was formerly known as Indivior PLC. Incorporated in 2014, Indivior Pharmaceuticals is headquartered in North Chesterfield, Virginia.
Indivior Pharmaceuticals, Inc. is a healthcare company focused on developing, manufacturing, and selling buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders globally. Its core marketed products include SUBLOCADE, a buprenorphine extended-release monthly injection, and SUBOXONE Film, a buprenorphine and naloxone sublingual film. The company also manufactures SUBOXONE Tablet and SUBUTEX Tablet for opioid use disorder (OUD). In its pipeline, Indivior is developing INDV-2000, a selective orexin-1 receptor antagonist in Phase 2 clinical trials for moderate to severe OUD, and INDV-6001, a buprenorphine-based long-acting injectable for OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC and changed its name in January 2026.
Where is Indivior Pharmaceuticals (INDV) listed and what currency does it trade in?
Indivior Pharmaceuticals, Inc. is listed on the NasdaqGS exchange under the ticker symbol INDV. The company trades in United States Dollars (USD). Its headquarters are located in North Chesterfield, Virginia, United States. As a US-based company listed on a major American exchange, its stock is primarily traded in USD, making it accessible to investors in the United States and internationally through US markets.
What sector and industry does Indivior Pharmaceuticals (INDV) belong to?
Indivior Pharmaceuticals operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This means the company is involved in the development and production of specialized pharmaceutical products, particularly generic or specialty drugs. In Indivior's case, its focus is on buprenorphine-based medications for opioid dependence, which falls under specialty generic drugs. The company's products are prescription-based and target a specific therapeutic area—substance use disorders—rather than a broad range of conditions.
Where is Indivior Pharmaceuticals (INDV) headquartered and what markets does it serve?
Indivior Pharmaceuticals, Inc. is headquartered in North Chesterfield, Virginia, United States. The company serves global markets, as indicated by its description stating it provides drugs for the treatment of opioid dependence and related disorders globally. While its primary operations are based in the US, its products are distributed internationally. The company's focus on opioid use disorder (OUD) addresses a significant public health issue worldwide, and its pipeline includes collaborations such as with Alar Pharmaceuticals Inc., suggesting a reach beyond domestic borders.
How does Indivior Pharmaceuticals (INDV) generate revenue?
Indivior Pharmaceuticals generates revenue primarily through the development, manufacture, and sale of buprenorphine-based prescription drugs for treating opioid dependence and related disorders. Its core marketed products include SUBLOCADE (a monthly injection) and SUBOXONE Film (a sublingual film), as well as SUBOXONE Tablet and SUBUTEX Tablet. These products are prescribed for opioid use disorder (OUD), and the company earns revenue from sales to healthcare providers, pharmacies, and distributors. Additionally, Indivior has a pipeline of products in development, such as INDV-2000 and INDV-6001, which may generate future revenue upon approval and commercialization. The company's business model focuses on specialty pharmaceuticals for substance use disorders, a niche but critical area of healthcare.